ImmunoPrecise Antibodies Ltd.
IPA
$0.3918
-$0.0082-2.05%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.49M | 3.84M | 4.76M | 4.61M | 4.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.49M | 3.84M | 4.76M | 4.61M | 4.53M |
| Cost of Revenue | 1.97M | 2.12M | 2.47M | 2.24M | 2.35M |
| Gross Profit | 2.52M | 1.72M | 2.29M | 2.37M | 2.18M |
| SG&A Expenses | 3.30M | 3.39M | 3.71M | 3.58M | 3.11M |
| Depreciation & Amortization | 449.00K | 442.60K | 516.60K | 525.10K | 523.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.57M | 7.16M | 7.37M | 7.08M | 6.61M |
| Operating Income | -2.08M | -3.31M | -2.61M | -2.47M | -2.08M |
| Income Before Tax | -2.24M | -3.49M | -13.87M | -2.56M | -1.91M |
| Income Tax Expenses | -370.60K | -566.70K | -572.60K | -382.90K | -134.00K |
| Earnings from Continuing Operations | -1.87M | -2.92M | -13.30M | -2.18M | -1.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.87M | -2.92M | -13.30M | -2.18M | -1.77M |
| EBIT | -2.08M | -3.31M | -2.61M | -2.47M | -2.08M |
| EBITDA | -1.42M | -2.66M | -1.95M | -1.78M | -1.08M |
| EPS Basic | -0.07 | -0.11 | -0.50 | -0.08 | -0.07 |
| Normalized Basic EPS | -0.05 | -0.08 | -0.07 | -0.06 | -0.05 |
| EPS Diluted | -0.07 | -0.11 | -0.50 | -0.08 | -0.07 |
| Normalized Diluted EPS | -0.05 | -0.08 | -0.07 | -0.06 | -0.05 |
| Average Basic Shares Outstanding | 28.13M | 27.13M | 26.65M | 25.80M | 25.05M |
| Average Diluted Shares Outstanding | 28.13M | 27.13M | 26.65M | 25.80M | 25.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
